Recent studies have shown that chemotherapeutic agents induce the expression of the negative checkpoint ligand PD-L1 in cancer cells and that blocking of the PD-L1/PD-1 checkpoint increases the responsiveness of NSCLC to chemotherapy in patients [18]. This evidence concerns the gene PDCD1 and cancer.